Earnings per Share (EPS) (Basic): A company's net earnings or losses attributable to common shareholders per basic share basis.
Atrium Therapeutics, Inc. (RNA) had Earnings per Share (EPS) (Basic) of $-1.18 for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$3.00M |
|
$-20.19M |
|
-- |
|
$3.00M |
|
$25.62M |
|
$-22.62M |
|
$2.43M |
|
$-20.19M |
|
$-20.19M |
|
$-20.19M |
|
$-20.19M |
|
$-20.19M |
|
$-20.19M |
|
$-22.62M |
|
$-22.52M |
|
17.11M |
|
17.11M |
|
|
Earnings per Share (EPS) (Basic) |
$-1.18 |
$-1.18 |
|
| Balance Sheet Financials | |
$275.05M |
|
$4.07M |
|
$5.46M |
|
$280.51M |
|
$31.51M |
|
-- |
|
$34.43M |
|
$65.94M |
|
$214.58M |
|
$214.58M |
|
$214.58M |
|
17.11M |
|
| Cash Flow Statement Financials | |
$-35.07M |
|
$-193.69M |
|
$301.50M |
|
-- |
|
$72.75M |
|
$72.75M |
|
$13.11M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.73 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-752.93% |
|
-752.93% |
|
-- |
|
-671.97% |
|
-671.97% |
|
$-37.20M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-9.41% |
|
-9.41% |
|
-7.20% |
|
-9.41% |
|
$12.54 |
|
$-2.17 |
|
$-2.05 |
|